Agios Pharmaceuticals, Inc. (AGIO) |
|
24.75 -0.02 (-0.08%)
|
09-29 16:00 |
|
Open: |
24.97 |
Pre. Close: |
24.77 |
|
High:
|
25.12 |
Low:
|
24.495 |
|
Volume:
|
417,129 |
Market Cap:
|
1,376(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:25:43 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 31.29 One year: 33.27 |
| Support: |
Support1: 24.04 Support2: 20 |
| Resistance: |
Resistance1: 26.79 Resistance2: 28.48 |
| Pivot: |
25.43  |
| Moving Average: |
MA(5): 24.56 MA(20): 25.76
MA(100): 26.42 MA(250): 26.52 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 17.7 %D(3): 13.9 |
| RSI: |
RSI(14): 39.2 |
| 52-week: |
High: 31.87 Low: 21.06 |
| Average Vol(K): |
3-Month: 344 (K) 10-Days: 280 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AGIO ] has closed above bottom band by 33.7%. Bollinger Bands are 47.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
25.15 - 25.29 |
25.29 - 25.42 |
|
Low:
|
24.17 - 24.32 |
24.32 - 24.46 |
|
Close:
|
24.52 - 24.78 |
24.78 - 25 |
|
Company Description |
|
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Sat, 30 Sep 2023
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones ... - MarketBeat
Wed, 27 Sep 2023
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF ... - Nasdaq
Mon, 25 Sep 2023
Noteworthy Monday Option Activity: MU, AGIO, AMR - Nasdaq
Wed, 20 Sep 2023
Nordea Investment Management AB Decreases Stock Position in ... - MarketBeat
Tue, 19 Sep 2023
Duality Advisers LP Takes $566000 Position in Agios ... - MarketBeat
Tue, 12 Sep 2023
Armistice Capital LLC Buys 710000 Shares of Agios ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
56 (M) |
|
% Held by Insiders
|
5.168e+007 (%) |
|
% Held by Institutions
|
1.4 (%) |
|
Shares Short
|
6,050 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.6718e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
859.2 |
|
Return on Equity (ttm)
|
-20.1 |
|
Qtrly Rev. Growth
|
2.015e+007 |
|
Gross Profit (p.s.)
|
21.26 |
|
Sales Per Share
|
-21.18 |
|
EBITDA (p.s.)
|
1.32e+007 |
|
Qtrly Earnings Growth
|
-3.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-299 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-1.17 |
|
Price to Cash Flow
|
1.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
5.9e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
